Harmonized Monitoring of Antimicrobial Resistance in Salmonella and Campylobacter

The antimicrobials included in the 2021 report followed the panel of antimicrobials from the EU protocol for harmonised monitoring of AMR in human Salmonella and Campylobacter isolates (ECDC, 2016 , 2021 ). The priority panel for Campylobacter includes ciprofloxacin, erythromycin, tetracyclines and, since June 2016, gentamicin. Gentamicin is recommended for screening of invasive isolates and was added to the priority panel after a EUCAST ECOFF became available for disk diffusion for C. jejuni. Co‐amoxiclav (combination drug with amoxicillin and clavulanic acid) was included from the list of optional antimicrobials. In 2021, all reporting countries except Iceland tested the isolates against the three main antimicrobials ciprofloxacin, erythromycin and tetracycline (although some countries tested less than 10 isolates). In relation to C. jejuni isolates, sixteen reporting countries also tested for gentamicin and thirteen tested for co‐amoxiclav. With regards to C. coli isolates, thirteen reporting countries also tested these isolates for gentamicin and six tested for co‐amoxiclav (Annex B, Tables 1 and 2)